Orion Oyj (OTCMKTS:ORINY) Posts Quarterly Earnings Results

Orion Oyj (OTCMKTS:ORINY) issued its quarterly earnings results on Tuesday. The company reported $0.28 earnings per share (EPS) for the quarter, Zacks reports. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%.

Orion Oyj Trading Down 0.7 %

Shares of ORINY stock opened at $27.03 on Wednesday. The business’s fifty day moving average price is $24.73 and its 200 day moving average price is $25.11. The firm has a market capitalization of $7.63 billion, a PE ratio of 21.45 and a beta of 0.24. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. Orion Oyj has a 1-year low of $17.50 and a 1-year high of $28.55.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research lowered Orion Oyj to a “hold” rating in a report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.